Article

Synergistic effects of inhibitors targeting PI3K and Aurora Kinase A in preclinical inflammatory breast cancer models

2023-08-13

Abstract excerpt

<h4>Background</h4> Inflammatory breast cancer (IBC) is an aggressive clinical subtype of breast cancer often diagnosed in young women. Lymph node and distant metastases are frequently detected at diagnosis of IBC, and improvements in systemic therapies are needed. For IBC that lack hormone or HER2 expression, no targeted therapies are available. Since the phosphatidyl inositol 3’ kinase (PI3K) pathway is frequen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: de276ff9-7f7a-550a-b5a8-64faa490bb7e
DOI: 10.1101/2023.08.11.552992

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Synergistic effects of inhibitors targeting PI3K and Aurora Kinase A in preclinical inflammatory breast cancer modelsDOI 10.1101/2023.08.11.552992Read

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.Semantic proximity Read

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Semantic proximity Read

Targeting PI3K Signaling in Combination Cancer Therapy.Semantic proximity Read

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read

The Promise of Combining Inhibition of PI3K and PARP as Cancer TherapySemantic proximity Read

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Semantic proximity Read

Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.Semantic proximity Read

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.Semantic proximity Read

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.Semantic proximity Read

PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.Semantic proximity Read

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitorSemantic proximity Read

HDAC inhibitors target IRS4 to enhance anti-androgen receptor (AR) therapy in AR-positive triple negative breast cancerSemantic proximity Read